BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 16, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Feb. 26, 2021

View Archived Issues
Illustration of digital syringe

Nference, Mayo Clinic study ties prior vaccinations to COVID-19 defense

A new study by Mayo Clinic and Nference Inc. researchers suggests that prior childhood and adult vaccinations for illnesses such as polio, measles and flu may provide protection against COVID-19 infection. The study, which analyzed patient data using Nference artificial intelligence (AI) software, underscores the critical role immunizations play in curbing the spread of diseases and preventing future pandemics. “What we discovered represents compelling evidence that vaccinations are a critical element in prevention of disease, even diseases one doesn’t anticipate,” said Venky Soundararajan, co-founder and chief scientific officer of the Cambridge, Mass.-based company. Read More
IPO puzzle pieces

Vuno soars in $33.4M IPO as investors affirm AI’s potential

HONG KONG – Vuno Inc. saw its shares soar on their first day of trading on the Kosdaq board with a $33.4 million IPO. The shares closed at ₩32,150 (US$28.89) on Feb. 26. Vuno had priced the 1.8 million new shares on offer at ₩21,000, exceeding its desired range of ₩15,000 to ₩19,500 and raising ₩37.8 billion, or $33.4 million, to boot. Read More
eu-european-union-flag1.png

EU regulatory system under enormous pressure as compliance deadline approaches

The well-known overhaul of the European Union’s (EU) med-tech regulatory system was already a massive lift before the events of 2020, but the three-year transition period begins in 90 days with a large overhang of issues. Among these is that the ISO 14971 risk management standard is not recognized in the EU, and Adrian Keene, director of EU services for North American Science Associates Inc., said on a Feb. 25 webinar that “anything manufacturers can do to smooth the pathway” for device certification and recertification “is worth considering.” Read More
Mobile app on smart phone

January AI sweetens its prospects with $8.8M in new funding

Big name investors think January AI Inc. is onto something sweet with its breakthrough diabetes management technology. Investors added $8.8 million to the company's finances, bringing its total capital raised to date to $21 million. Felicis Ventures, which previously invested in Fitbit and Modern Health, joined Hand Capital and Marc Benioff in the latest round. Read More
Product image

Truvian Sciences scores $105M in series C round to advance blood testing system

Truvian Sciences Inc. has closed more than $105 million in an oversubscribed series C financing round that will help jumpstart the evaluation of the company’s automated benchtop blood testing system. The round was led by TYH Ventures, Glen Tullman of 7wireventures, and Wittington Ventures. Read More

Lack of clinical trial diversity could have consequences

Drug and device companies dragging their feet on diversifying late-stage clinical trials could conceivably get a wake-up call in court or in FDA approval delays. Read More

Appointments and advancements for Feb. 26, 2021

New hires and promotions in the med-tech industry, including: Evolus, Modivcare, WW International. Read More

In the clinic for Feb. 26, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Silk Road Medical. Read More

Med-tech gainers and losers for Feb. 22-26, 2021

The top 10 med-tech stock gainers and losers for the week. Read More

Other news to note for Feb. 26, 2021

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aquarius Surgical Technologies, Healthmode, Htg Molecular Diagnostics, Inventiva, Materials and Machines, Medi-Tate, Mesa Biotech, Mind Medicine, Olympus, Picnichealth, Sirtex Medical, Surgical Lasers, Thermo Fisher, Vela Diagnostics. Read More

Regulatory actions for Feb. 26, 2021

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Fusion Robotics, Roche. Read More

Regulatory front for Feb. 26, 2021

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Neovasc snares second patent term extension; CMS drops CT image quality proposal; TGA opens docket for nanomaterials regulation; ATA supports OIG statement on telehealth. Read More

BioWorld MedTech’s Neurology Extra for Feb. 26, 2021

Keeping you up to date on recent developments in neurology, including: Preventing seizures after brain injury could slow or stop the onset of dementia, Researchers find new signaling pathway in neurons, Developing a cost effective, less invasive method to diagnose potential for Alzheimer’s disease. Read More

BioWorld MedTech Patent Highlights: Week 7

BioWorld MedTech presents Patent Highlights, an excerpt of the most important med-tech patents from this week's Cortellis Patents Gazette. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 15, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 15, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Businesswoman pressing dollar sign on touchscreen

    JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

    BioWorld
    It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing